F-star is a biopharmaceutical company developing novel bispecific antibody products to improve the treatment of cancer.
|Telephone:||+44 (0)1223 497 400|
|Address:||Eddeva B920, Babraham Research Campus, Babraham|
|Membership type:||Corporate 51+ (£1,000+VAT pa)|
F-star is a leader in the development of novel bispecific antibodies
F-star is an oncology-focused biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve the standard of care for patients.
Our Modular Antibody Technology™ allows us to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. It combines the power of our Fcab™ technology with traditional antibodies to identify the most appropriate target combinations, thus providing the opportunity to deliver products with the greatest therapeutic advantage to patients.
Developing genuine bispecific monoclonal antibodies
Our technology capitalizes on decades of experience with traditional antibody technology, while overcoming the limitations in the development and manufacture of bispecific antibodies.
Our experienced and proven team is well-positioned to leverage the strength of our proprietary bispecific antibody platform and to lead the advancement of Fcab-based antibodies to the clinic.
F-star funding secured through investors and strategic partnerships
To date F-star has raised more than €38 million in venture capital from VC investors: Aescap Venture, Atlas Venture, Novo Ventures, and TVM Capital; as well as from corporate investors: Merck Serono Ventures, MP Healthcare Venture Management, and SR One.
The company has two major alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. The partnerships provide F-star with technology access fees, research funding, plus development and commercialization milestones, and royalties.
An asset-centric vehicle (“F-star Alpha Ltd.”) has been established to create greater commercial and financial flexibility for F-star, the investors, and future partners.
A “Fierce 15” most promising private biotech company
In 2011, F-star was selected by the industry newsletter FierceBiotech as one of the Fierce 15 winners, designating it as one of the most promising private biotechnology companies in the industry.
F-star was founded in 2006, based on the work of Professor Florian Rüker at BOKU (the University of Natural Resources and Life Sciences) in Vienna, with which it maintains close ties.
F-star currently employs more than 30 people at its research site in Cambridge, UK.
F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, this week won “Best Partnership Alliance” at the Scrip Awards ceremony.
30 November 2018Read in full
F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and technology company, for the development and commercialisation of five bispecific immuno-oncology antibodies (mAb2 ™).
5 June 2017Read in full
F-star, a biopharmaceutical company focused on oncology and immunooncology, today announced the initiation of a phase 1 clinical study of FS102, its lead compound for treatment of HER2-positive breast and gastric cancer.
9 January 2015Read in full